Arbutus Biopharma
Open
$4.37
Prev. Close
$4.36
High
$4.39
Low
$4.37
Market Snapshot
$858.15M
5.3
-0.38
$6.17M
19
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, British Columbia and currently employs 19 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, British Columbia and currently employs 19 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Recently from Cashu
Arbutus Biopharma's Patent Settlement Propels mRNA Innovation in Biopharmaceutical Sector
Arbutus Biopharma and the Impact of mRNA Patent Settlement on the Biopharmaceutical Sector Arbutus Biopharma Corporation plays a vital role in the ongoing development and innovation of mRNA technology…
Arbutus Biopharma Settles with Moderna, Advancing mRNA Technology Collaboration
Arbutus Biopharma Facilitates Progress in mRNA Technology Through Settlement with Moderna Arbutus Biopharma Corporation enters a pivotal phase as it collaborates with Moderna Inc. under a settlement a…
Arbutus Biopharma: High-Risk Investment with Potential for Significant Rewards and Losses
Arbutus Biopharma Faces High-Risk Assessment Amid Market Commentary In recent market commentary, Arbutus Biopharma stands out as a high-risk investment, referred to as "the ultimate spec." This charac…